Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines.

The enzymatic activity of the human immunodeficiency type 1 (HIV-1) protease (PR) is crucial to render HIV-1 virions mature and infectious. Hence, genetic intervention strategies based on trans-dominant (td) variants of the HIV-1 PR might be an alternative to current pharmacological and gene therapy...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

I whakaputaina i:	J Virol
Ngā kaituhi matua:	Junker, U, Escaich, S, Plavec, I, Baker, J, McPhee, F, Rose, J R, Craik, C S, Böhnlein, E
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	American Society for Microbiology (ASM) 1996
Ngā marau:	Research Article
Urunga tuihono:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC190846/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8892897/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.70.11.7765-7772.1996
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!